Recombinant BCG expressing Mycobacterium tuberculosis major extracellular proteins
Related Experiment Video
Updated: Aug 17, 2026
Expression of Exogenous Antigens in the Mycobacterium bovis BCG Vaccine via Non-genetic Surface Decoration with the Avidin-biotin System
Published on: January 31, 2018
1Department of Medicine, School of Medicine, University of California-Los Angeles, Los Angeles, CA 90095, USA. mhorwitz@mednet.ucla.edu
Abstract:
rBCG30, the first vaccine against tuberculosis demonstrated more potent than BCG in preclinical studies, is the prototype of a class of vaccines that utilize BCG as a host organism for expressing and secreting Mycobacterium tuberculosis major extracellular proteins. The vaccine is based on the concept that extracellular proteins of intracellular pathogens are key immunoprotective molecules. rBCG30, which expresses and secretes large amounts of the M. tuberculosis 30 kDa major secretory protein, is currently in human clinical trials.
